Literature DB >> 27045138

In Pulmonary Arterial Hypertension, Reduced BMPR2 Promotes Endothelial-to-Mesenchymal Transition via HMGA1 and Its Target Slug.

Rachel K Hopper1, Jan-Renier A J Moonen1, Isabel Diebold1, Aiqin Cao1, Christopher J Rhodes1, Nancy F Tojais1, Jan K Hennigs1, Mingxia Gu1, Lingli Wang1, Marlene Rabinovitch2.   

Abstract

BACKGROUND: We previously reported high-throughput RNA sequencing analyses that identified heightened expression of the chromatin architectural factor High Mobility Group AT-hook 1 (HMGA1) in pulmonary arterial endothelial cells (PAECs) from patients who had idiopathic pulmonary arterial hypertension (PAH) in comparison with controls. Because HMGA1 promotes epithelial-to-mesenchymal transition in cancer, we hypothesized that increased HMGA1 could induce transition of PAECs to a smooth muscle (SM)-like mesenchymal phenotype (endothelial-to-mesenchymal transition), explaining both dysregulation of PAEC function and possible cellular contribution to the occlusive remodeling that characterizes advanced idiopathic PAH. METHODS AND
RESULTS: We documented increased HMGA1 in PAECs cultured from idiopathic PAH versus donor control lungs. Confocal microscopy of lung explants localized the increase in HMGA1 consistently to pulmonary arterial endothelium, and identified many cells double-positive for HMGA1 and SM22α in occlusive and plexogenic lesions. Because decreased expression and function of bone morphogenetic protein receptor 2 (BMPR2) is observed in PAH, we reduced BMPR2 by small interfering RNA in control PAECs and documented an increase in HMGA1 protein. Consistent with transition of PAECs by HMGA1, we detected reduced platelet endothelial cell adhesion molecule 1 (CD31) and increased endothelial-to-mesenchymal transition markers, αSM actin, SM22α, calponin, phospho-vimentin, and Slug. The transition was associated with spindle SM-like morphology, and the increase in αSM actin was largely reversed by joint knockdown of BMPR2 and HMGA1 or Slug. Pulmonary endothelial cells from mice with endothelial cell-specific loss of Bmpr2 showed similar gene and protein changes.
CONCLUSIONS: Increased HMGA1 in PAECs resulting from dysfunctional BMPR2 signaling can transition endothelium to SM-like cells associated with PAH.
© 2016 American Heart Association, Inc.

Entities:  

Keywords:  HMGA1 protein; endothelial-to-mesenchymal transition; hypertension, pulmonary

Mesh:

Substances:

Year:  2016        PMID: 27045138      PMCID: PMC4856565          DOI: 10.1161/CIRCULATIONAHA.115.020617

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  50 in total

1.  The transcription factor snail controls epithelial-mesenchymal transitions by repressing E-cadherin expression.

Authors:  A Cano; M A Pérez-Moreno; I Rodrigo; A Locascio; M J Blanco; M G del Barrio; F Portillo; M A Nieto
Journal:  Nat Cell Biol       Date:  2000-02       Impact factor: 28.824

2.  Mature vascular endothelium can give rise to smooth muscle cells via endothelial-mesenchymal transdifferentiation: in vitro analysis.

Authors:  Maria G Frid; Vishakha A Kale; Kurt R Stenmark
Journal:  Circ Res       Date:  2002-06-14       Impact factor: 17.367

3.  RNA Sequencing Analysis Detection of a Novel Pathway of Endothelial Dysfunction in Pulmonary Arterial Hypertension.

Authors:  Christopher J Rhodes; Hogune Im; Aiqin Cao; Jan K Hennigs; Lingli Wang; Silin Sa; Pin-I Chen; Nils P Nickel; Kazuya Miyagawa; Rachel K Hopper; Nancy F Tojais; Caiyun G Li; Mingxia Gu; Edda Spiekerkoetter; Zhaoying Xian; Rui Chen; Mingming Zhao; Mark Kaschwich; Patricia A Del Rosario; Daniel Bernstein; Roham T Zamanian; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Am J Respir Crit Care Med       Date:  2015-08-01       Impact factor: 21.405

4.  Pulmonary artery endothelial abnormalities in patients with congenital heart defects and pulmonary hypertension. A correlation of light with scanning electron microscopy and transmission electron microscopy.

Authors:  M Rabinovitch; T Bothwell; B N Hayakawa; W G Williams; G A Trusler; R D Rowe; P M Olley; E Cutz
Journal:  Lab Invest       Date:  1986-12       Impact factor: 5.662

5.  Familial primary pulmonary hypertension (gene PPH1) is caused by mutations in the bone morphogenetic protein receptor-II gene.

Authors:  Z Deng; J H Morse; S L Slager; N Cuervo; K J Moore; G Venetos; S Kalachikov; E Cayanis; S G Fischer; R J Barst; S E Hodge; J A Knowles
Journal:  Am J Hum Genet       Date:  2000-07-20       Impact factor: 11.025

6.  Heterozygous germline mutations in BMPR2, encoding a TGF-beta receptor, cause familial primary pulmonary hypertension.

Authors:  K B Lane; R D Machado; M W Pauciulo; J R Thomson; J A Phillips; J E Loyd; W C Nichols; R C Trembath
Journal:  Nat Genet       Date:  2000-09       Impact factor: 38.330

7.  Histopathology of primary pulmonary hypertension. A qualitative and quantitative study of pulmonary blood vessels from 58 patients in the National Heart, Lung, and Blood Institute, Primary Pulmonary Hypertension Registry.

Authors:  G G Pietra; W D Edwards; J M Kay; S Rich; J Kernis; B Schloo; S M Ayres; E H Bergofsky; B H Brundage; K M Detre
Journal:  Circulation       Date:  1989-11       Impact factor: 29.690

8.  The oncogenic properties of the HMG-I gene family.

Authors:  L J Wood; J F Maher; T E Bunton; L M Resar
Journal:  Cancer Res       Date:  2000-08-01       Impact factor: 12.701

9.  Primary pulmonary hypertension is associated with reduced pulmonary vascular expression of type II bone morphogenetic protein receptor.

Authors:  Carl Atkinson; Susan Stewart; Paul D Upton; Rajiv Machado; Jennifer R Thomson; Richard C Trembath; Nicholas W Morrell
Journal:  Circulation       Date:  2002-04-09       Impact factor: 29.690

10.  Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro.

Authors:  E Arciniegas; A B Sutton; T D Allen; A M Schor
Journal:  J Cell Sci       Date:  1992-10       Impact factor: 5.285

View more
  84 in total

1.  Vascular Endothelial Receptor Tyrosine Phosphatase: Identification of Novel Substrates Related to Junctions and a Ternary Complex with EPHB4 and TIE2.

Authors:  Hannes C A Drexler; Matthias Vockel; Christian Polaschegg; Maike Frye; Kevin Peters; Dietmar Vestweber
Journal:  Mol Cell Proteomics       Date:  2019-08-19       Impact factor: 5.911

2.  Patient-Specific iPSC-Derived Endothelial Cells Uncover Pathways that Protect against Pulmonary Hypertension in BMPR2 Mutation Carriers.

Authors:  Mingxia Gu; Ning-Yi Shao; Silin Sa; Dan Li; Vittavat Termglinchan; Mohamed Ameen; Ioannis Karakikes; Gustavo Sosa; Fabian Grubert; Jaecheol Lee; Aiqin Cao; Shalina Taylor; Yu Ma; Zhixin Zhao; James Chappell; Rizwan Hamid; Eric D Austin; Joseph D Gold; Joseph C Wu; Michael P Snyder; Marlene Rabinovitch
Journal:  Cell Stem Cell       Date:  2016-12-22       Impact factor: 24.633

3.  PPARγ Interaction with UBR5/ATMIN Promotes DNA Repair to Maintain Endothelial Homeostasis.

Authors:  Caiyun G Li; Cathal Mahon; Nathaly M Sweeney; Erik Verschueren; Vivek Kantamani; Dan Li; Jan K Hennigs; David P Marciano; Isabel Diebold; Ossama Abu-Halawa; Matthew Elliott; Silin Sa; Feng Guo; Lingli Wang; Aiqin Cao; Christophe Guignabert; Julie Sollier; Nils P Nickel; Mark Kaschwich; Karlene A Cimprich; Marlene Rabinovitch
Journal:  Cell Rep       Date:  2019-01-29       Impact factor: 9.423

4.  Phenotypically Silent Bone Morphogenetic Protein Receptor 2 Mutations Predispose Rats to Inflammation-Induced Pulmonary Arterial Hypertension by Enhancing the Risk for Neointimal Transformation.

Authors:  Wen Tian; Xinguo Jiang; Yon K Sung; Eric Shuffle; Ting-Hsuan Wu; Peter N Kao; Allen B Tu; Peter Dorfmüller; Aiqin Cao; Lingli Wang; Gongyong Peng; Yesl Kim; Patrick Zhang; James Chappell; Shravani Pasupneti; Petra Dahms; Peter Maguire; Hassan Chaib; Roham Zamanian; Marc Peters-Golden; Michael P Snyder; Norbert F Voelkel; Marc Humbert; Marlene Rabinovitch; Mark R Nicolls
Journal:  Circulation       Date:  2019-08-29       Impact factor: 29.690

Review 5.  Translating Research into Improved Patient Care in Pulmonary Arterial Hypertension.

Authors:  Sébastien Bonnet; Steeve Provencher; Christophe Guignabert; Frédéric Perros; Olivier Boucherat; Ralph Theo Schermuly; Paul M Hassoun; Marlene Rabinovitch; Mark R Nicolls; Marc Humbert
Journal:  Am J Respir Crit Care Med       Date:  2017-03-01       Impact factor: 21.405

Review 6.  Transcription factors, transcriptional coregulators, and epigenetic modulation in the control of pulmonary vascular cell phenotype: therapeutic implications for pulmonary hypertension (2015 Grover Conference series).

Authors:  Soni S Pullamsetti; Frédéric Perros; Prakash Chelladurai; Jason Yuan; Kurt Stenmark
Journal:  Pulm Circ       Date:  2016-12       Impact factor: 3.017

Review 7.  Vascular Cells in Blood Vessel Wall Development and Disease.

Authors:  R Mazurek; J M Dave; R R Chandran; A Misra; A Q Sheikh; D M Greif
Journal:  Adv Pharmacol       Date:  2016-10-14

Review 8.  The Vascular Wall: a Plastic Hub of Activity in Cardiovascular Homeostasis and Disease.

Authors:  Cassandra P Awgulewitsch; Linh T Trinh; Antonis K Hatzopoulos
Journal:  Curr Cardiol Rep       Date:  2017-06       Impact factor: 2.931

Review 9.  Role of extracellular matrix in the pathogenesis of pulmonary arterial hypertension.

Authors:  Thenappan Thenappan; Stephen Y Chan; E Kenneth Weir
Journal:  Am J Physiol Heart Circ Physiol       Date:  2018-08-24       Impact factor: 4.733

Review 10.  Pharmacology of Pulmonary Arterial Hypertension: An Overview of Current and Emerging Therapies.

Authors:  Monika Spaczyńska; Susana F Rocha; Eduardo Oliver
Journal:  ACS Pharmacol Transl Sci       Date:  2020-07-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.